Direct Medical Costs in Patients with Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) in Colombia

Speaker(s)

López-Cabra C1, Roa M1, Torres L1, Salcedo Mejía F2, Camerano R3, Chaparro Vivanco FA2, Gómez De la Rosa F2, Alvis Zakzuk NJ4, Alvis Zakzuk NR5, Fernandez Mercado J6, Estrada H7, Estrada S7, Martínez E7, Marrugo R1
1Bayer, Bogotá, CUN, Colombia, 2ALZAK, Cartagena, Bolívar, Colombia, 3ALZAK, Bogotá, CUN, Colombia, 4Universidad de la Costa, Barranquilla, Atlántico, Colombia, 5ALZAK Foundation, Cartagena, Bolivar, Colombia - Institucion Universitaria Mayor de Cartagena, Cartagena, Bolívar, Colombia, 6Secretaria de Salud Bolivar Colombia -University of Cartagena, Cartagena, BOL, Colombia, 7Ciro-Caribe, Centro Radio Oncológico del Caribe, Universidad de Cartagena, Cartagena, Colombia

OBJECTIVES: To describe the direct medical costs of patients diagnosed with prostate cancer at nmCRPC stage affiliated to a health insurance company and treated in a regional reference center in Cartagena, Colombia.

METHODS: A retrospective, cross-sectional analysis study using macro costing method using records between 2021-2022 from a health insurance company. Patients without any treatment with chemotherapy + antiandrogens and/or bone protectors were categorized as non-metastatic patients (nmCRPC). An estimate of frequency of use of services and the aggregation of the cost for services from the insurer's perspective using the Health Care Delivery Records (RIPS) public database[1] was calculated. Finally, an adjustment for differences in average cost estimates is made, using identifiable characteristics. A generalized linear model with gamma distribution was performed to estimate cost ratios between different stages. An exchange rate of COP$3,932.59 per-USD (2023) was used.

[1] Ministry of Health in Colombia. Sistema de Información de Prestaciones de Salud – RIPS. URL: https://www.minsalud.gov.co/proteccionsocial/Paginas/rips.aspx

RESULTS: Average annual cost of a patient at non-metastatic stage is US$368.66 (IQR US$138.74 -US$1,684.76). Reporting the cost by stage of the disease, patients with metastatic stage presented median costs 4.8 times the median costs (US$1,798.12) of non-metastatic patients, except the radiology treatment which presents an average cost approximately 2 times higher for non-metastatic patients.

CONCLUSIONS: In general, the cost of a patient with metastasis is greater versus a non-metastatic one. Nonetheless, when surgical procedures and radiotherapy costs are disaggregated, patients in the non-metastatic stage of the disease, present a major expenditure for the health care system.

Code

EE328

Topic

Economic Evaluation

Disease

Oncology